Biotech Values

[jq1234]

The Denosumab phase-3 trial due to report any day has progression-free survival as the primary endpoint.

It's Bone Metastasis-Free Survival. But patients enrolled in the trials couldn't have prior or current evidence of radiographically detectable bone metastasis, which is entirely different from EXEL184.

I don't know how else to convince you Denosumab and XL184 are NOT competing drugs.